The tenth round of China’s national centralized drug procurement program has marked a watershed moment in the country’s healthcare reform efforts, achieving historic price reductions across 62 drug varieties. The scale of these reductions has been remarkable - some medications that previously cost around 200 yuan per dose have plummeted to just 15 yuan, representing drops of over 90%.
